Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.
We report a case of severe thrombocytopenia following pegylated interferon-alpha 2a (Peg-IFN-alpha 2a) treatment of hepatitis C virus infection and summarize the clinical characteristics of 16 cases of IFN-alpha induced severe thrombocytopenia and its immune-mediated mechanism. Discontinuation of IFN-alpha and early administration of immunosuppressants are the effective therapy for IFN-alpha induced severe thrombocytopenia.
Li
Li
L
Tumor Biotherapy Ward of Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Han
Da-Kang
DK
Lu
Jun
J
D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a